Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Given Average Rating of “Moderate Buy” by Brokerages
by Doug Wharley · The Cerbat GemShares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) have received an average rating of “Moderate Buy” from the five ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $25.00.
Several research analysts have recently weighed in on the stock. Guggenheim increased their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of Nanobiotix in a research report on Thursday, March 12th.
Check Out Our Latest Stock Analysis on NBTX
Nanobiotix Stock Performance
Nanobiotix stock opened at $31.04 on Monday. The stock has a fifty day moving average price of $28.30 and a 200 day moving average price of $23.40. Nanobiotix has a 52 week low of $2.99 and a 52 week high of $41.89.
Nanobiotix (NASDAQ:NBTX – Get Free Report) last issued its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $3.42 million during the quarter. On average, analysts anticipate that Nanobiotix will post -1.18 earnings per share for the current year.
Institutional Trading of Nanobiotix
A number of institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC purchased a new position in shares of Nanobiotix in the 4th quarter worth $390,000. Royal Bank of Canada grew its position in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after acquiring an additional 2,500 shares during the period. Marshall Wace LLP acquired a new stake in Nanobiotix during the fourth quarter worth about $220,000. Finally, Optiver Holding B.V. acquired a new stake in Nanobiotix during the third quarter worth about $101,000. 38.81% of the stock is currently owned by institutional investors and hedge funds.
About Nanobiotix
Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.
Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.